Core Viewpoint - The optical communication sector is experiencing a significant rise, driven by the increasing demand for high-speed optical transceiver modules due to the growth of AI data centers and cloud computing infrastructure [1] Group 1: Stock Performance - Hongteng Precision (06088) increased by 7.01%, reaching HKD 5.65 [1] - Changfei Optical Fiber and Cable (06869) rose by 4.02%, reaching HKD 37.78 [1] - Cambridge Technology (06166) saw a 3.47% increase, reaching HKD 89.5 [1] - Huiju Technology (01729) grew by 0.59%, reaching HKD 17.12 [1] Group 2: Market Research Insights - TrendForce's latest report indicates that the global shipment of optical transceiver modules above 800G is expected to reach 24 million units by 2025 and nearly 63 million units by 2026, representing a growth of 2.6 times [1] - The report highlights a severe supply bottleneck in laser light sources at the upstream supply chain due to the high demand for 800G optical transceiver modules [1] Group 3: Industry Outlook - CICC believes that the AI technology revolution and energy revolution are driving demand from upstream raw materials to midstream manufacturing, leading to improved performance for listed companies [1] - The trend of growth in the industry remains upward, with a focus on domestic computing power, optical modules, and cloud computing infrastructure in December [1] - Applications to watch include robotics, consumer electronics, intelligent driving, and software applications as AI applications continue to be implemented [1]

Core Viewpoint - Cambridge Technology (06166) has announced plans to raise $100 million through the issuance of H-shares to support its U.S. subsidiary, CIG America, in enhancing R&D, business expansion, and global supply chain collaboration [1] Group 1: Fundraising and Investment Plans - The company intends to use the raised funds to purchase production equipment and expand high-speed optical module capacity in North America and Southeast Asia, thereby improving global delivery capabilities [1] - The funds will also be allocated to enhance overseas R&D scale and capabilities, accelerating the development and iteration of new technologies and products to ensure technological leadership [1] - Increased marketing efforts will be made to expand key markets and customers, building sales channels and customer service systems to support long-term high-speed growth [1] Group 2: Supply Chain and Operational Strategy - The company plans to strengthen strategic procurement and reserve of key components to stabilize and enhance the supply capacity of core components, ensuring stable delivery and rapid growth [1] - Participation in industry chain collaboration through strategic partnerships will be aimed at enhancing global supply chain security [1] - The funds will also be used to supplement operational capital [1]

Major Events - GuoXia Technology (02655) plans to conduct an IPO from December 8 to December 11, offering 33.85 million H-shares and introducing cornerstone investors such as Huikai Hong Kong [1] - Basilea Pharmaceutica AG (02616) has its drug Pujihua® (Pralsetinib Capsules) included in the National Medical Insurance Directory for 2025 [1] - Four Seasons Pharmaceutical (00460) sees its innovative drug XuanYueNing® included in the National Basic Medical Insurance Drug List for the first time [1] - Shanghai Pharmaceuticals (02607) successfully negotiates and includes Amisulpride Orally Disintegrating Tablets in the National Medical Insurance Directory [1] - Hansoh Pharmaceutical (03692) has its innovative drug Amelotex® approved for two new indications in the updated 2025 National Medical Insurance Directory [1] - Xiansheng Pharmaceutical (02096) sees EnzeShu® and EnDu® included in the updated National Medical Insurance Drug List [1] - Hutchison China MediTech (00013) has its drug Tazverik® included in the first edition of the National Commercial Health Insurance Innovative Drug List [1] - XuanZhu Biotechnology (02575) has its innovative drug XuanYueNing® included in the National Basic Medical Insurance Drug List for the first time [1] - Yino Pharmaceutical (02591) has its H-shares included in the list of eligible securities for the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect [1] - China Metallurgical Group (01618) and its subsidiaries plan to sell non-core business assets for approximately 60.68 billion yuan, focusing on core businesses in metallurgical engineering, non-ferrous metals, and mining engineering [1] - Cambridge Technology (06166) intends to invest a total of 405 million yuan to acquire and subscribe for shares in the Yangzhong Happiness Home Venture Capital Partnership Fund [1] Operating Performance - Dongfeng Motor Group (00489) reports cumulative automobile sales of 1.697 million units in the first 11 months, a year-on-year decrease of approximately 0.3% [2] - New天绿色能源 (00956) achieves a cumulative power generation of 1,336.89 million MWh in the first 11 months, an increase of 8.04% year-on-year [2] - Longyuan Power (00916) reports a cumulative power generation of approximately 6,909.64 million MWh in the first 11 months, a year-on-year growth of 0.41% [2] - Baolong Real Estate (01238) records a total contract sales of approximately 6.666 billion yuan in the first 11 months, a year-on-year decline of 43.2% [2]

Group 1 - The company plans to raise RMB 500 million through the issuance of H-shares to acquire a 99.99% stake in Yangzhong Xingfu Jiayuan Venture Capital Partnership, increasing its total subscribed capital to approximately RMB 400 million [1][2] - The partnership will focus on investments in emerging industries such as integrated circuits and artificial intelligence, particularly in the optical devices, chips, and core IC sectors, targeting early-stage and growth-stage companies [1][2] - The partnership will also have the ability to invest in high-quality overseas technology companies and allocate overseas assets, while funds during idle periods can be invested in various cash management tools recognized by the China Securities Regulatory Commission [1][2] Group 2 - This investment allows the company to leverage the resources and advantages of professional institutions in the investment field, aiming for medium to long-term investment returns while controlling risks [2] - By focusing on the optical devices, chips, and core IC sectors, the company aims to enhance its control over the upstream and downstream of the industry chain, improve technical capabilities, and increase market coverage and influence [2] - The investment strategy aligns with the company's long-term development strategy and fundraising plans, diversifying the investment portfolio and maximizing strategic and operational synergies [2]

本次投资是公司使用发行境外上市外资股(H 股)募集资金与专业机构共同进行的投资，能够充分利用专 业机构在投资领域的资源和优势，在合理控制风险的前提下，开展股权投资业务，以获取中长期投资回 报。同时，通过重点布局光器件、芯片及核心 IC 领域企业，能够加强公司对产业链上下游的掌控力， 提升公司的技术能力和供应链韧性，提高下游市场覆盖率和扩大市场影响力，多样化公司的投资组合及 最大化战略及经营协同效应，符合公司长远发展战略及募集资金使用规划。 智通财经APP讯，剑桥科技(06166)公布，公司拟以发行境外上市外资股(H 股)募集资金人民币 500 万元 受让陈璐持有的扬中幸福家园创业投资合伙企业(有限合伙)(以下简称"合伙企业")99.99%的财产份额(对 应认缴份额1亿元，已实缴出资 500 万元)，并作为有限合伙人以发行境外上市外资股(H股)募集资金增 加认缴份额3亿元。本次交易完成后，合伙企业认缴出资总额变更为约人民币4亿元，公司认缴出资4亿 元，占比99.9975%，合伙企业将纳入公司合并报表范围。 合伙企业的投资标的是集成电路、人工智能等先进制造、信息技术类新兴行业的未上市/挂牌成长性、 创新性企业，重 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 上海劍橋科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6166） 海外監管公告 關於受讓並參與認購投資基金份額暨與專業機構共同投資的公告 本公告乃根據《香港聯合交易所有限公司證券上市規則》第13.10B條而作出。 茲 載 列 上 海 劍 橋 科 技 股 份 有 限 公 司（「 本 公 司 」）在 上 海 證 券 交 易 所 網 站(www.sse.com.cn)及中國報章刊登的本公司關於受讓並參與認購投資基金份額暨 與專業機構共同投資的公告，僅供參閱。 承董事會命 上海劍橋科技股份有限公司 CIG SHANGHAI CO., LTD. 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： Gerald G Wong先生 董事長、執行董事及總經理（首席執行官） 上海，2025 ...

Core Viewpoint - Cambridge Technology (06166) plans to raise $100 million through the issuance of H-shares to enhance CIG America’s capabilities in R&D, business expansion, customer service, globalization, and supply chain collaboration [1] Funding Utilization - The $100 million raised will be allocated to several key areas: - Procurement of production equipment to expand high-speed optical module capacity in North America and Southeast Asia, enhancing global delivery capabilities [1] - Increasing overseas R&D scale and capabilities to accelerate the development and iteration of new technologies and products, ensuring technological leadership [1] - Strengthening marketing efforts to expand key markets and customers, building sales channels and customer service systems to support long-term high-speed growth [1] - Strategic procurement and reserve of key components to stabilize and enhance the supply capability of core components, ensuring stable and rapid delivery [1] - Participating in industry chain collaboration to enhance global supply chain security through strategic partnerships [1] - Supplementing operational funds to support ongoing business activities [1]

CIG SHANGHAI CO., LTD. 上海劍橋科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6166） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Gerald G Wong先生 董事長、執行董事及總經理（首席執行官） 上海，2025年12月8日 於本公告日期，本公司董事會包括：(i)執行董事Gerald G Wong先生、趙海波先 生、趙宏偉先生及張傑先生；(ii)獨立非執行董事秦桂森先生、劉貴松先生、姚明龍 先生及袁淑儀女士。 海外監管公告 第五屆董事會第二十三次會議決議公告 本公告乃根據《香港聯合交易所有限公司證券上市規則》第13.10B條而作出。 茲 載 列 上 海 劍 橋 科 技 股 份 有 限 公 司（「 本 公 司 」）在 上 海 證 券 交 易 所 網 站(www.sse.com.cn)及中國報章刊登的本公司第五屆董事會第二十三次會議決議公 告，僅供參閱。 承董事會命 上海劍橋科技股份有限公司 ...

關於向境外全資子公司增資的公告 本公告乃根據《香港聯合交易所有限公司證券上市規則》第13.10B條而作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 CIG SHANGHAI CO., LTD. 上海劍橋科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6166） 海外監管公告 茲 載 列 上 海 劍 橋 科 技 股 份 有 限 公 司（「 本 公 司 」）在 上 海 證 券 交 易 所 網 站(www.sse.com.cn)及中國報章刊登的本公司關於向境外全資子公司增資的公告， 僅供參閱。 承董事會命 上海劍橋科技股份有限公司 Gerald G Wong先生 董事長、執行董事及總經理（首席執行官） 上海，2025年12月8日 於本公告日期，本公司董事會包括：(i)執行董事Gerald G Wong先生、趙海波先 生、趙宏偉先生及張傑先生；(ii)獨立非執行董事秦桂森先生、劉貴松先生、姚明龍 先生及袁淑儀女士。 证券代码 ...

Market Overview - The Hong Kong stock market faced pressure, with the Hang Seng Index dropping over 1%, closing at 25,965.36 points, down 1.23% or 319.72 points, with a total turnover of HKD 2,062.3 million [1] - The Hang Seng China Enterprises Index fell by 1.25% to 9,083.53 points, while the Hang Seng Tech Index remained flat at 5,662.55 points [1] Blue Chip Performance - Baidu Group-SW (09888) led blue-chip stocks, rising 3.45% to HKD 125.8, contributing 8.38 points to the Hang Seng Index [2] - Other notable performers included SMIC (00981) up 2.94%, China Ping An (02318) up 2.15%, while China Construction Bank (00939) fell 4.01%, dragging the index down by 54.39 points [2] Sector Highlights - Large tech stocks generally declined, with Alibaba down over 1% and Tencent down 0.82% [3] - Chinese brokerage stocks rose against the trend, with Huatai Securities (06886) up 5.17% and GF Securities (01776) up 3.1% [3] - The light communication sector saw significant gains, with Huiju Technology rising over 7% [4] - Lithium stocks mostly increased, with Ganfeng Lithium (01772) up 6.95% and CATL (03750) up 3.28% [5] Regulatory Developments - The Chairman of the China Securities Regulatory Commission (CSRC) emphasized the need to accelerate the development of top-tier investment banks and institutions, indicating a potential easing of regulations for quality institutions [4] - The CSRC plans to optimize risk control indicators and moderately open up capital space and leverage limits, which could benefit leading brokerages [4] New Listings and Stock Movements - Two new stocks were listed, with Zhuoyue Ruixin (02687) surging 87.26% and Naxinwei (02676) declining 4.31% [7] - Restructured Energy (02570) faced a significant drop of 27.33% on its first trading day after the lock-up period ended [8] - Silver Pharma-B (02591) saw a decline of 14.32% following its inclusion in the Hong Kong Stock Connect [9] - Sutech (02498) performed well, rising 5.23% after securing a major order from FAW Toyota [10] Pharmaceutical Sector Updates - The National Healthcare Security Administration announced the addition of 114 new drugs to the 2025 National Medical Insurance Drug List, with a success rate of 88%, up from 76% in 2024 [6]